Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.85 |
| ▸ | HTR2C | P28335 | 2/20 | 0.85 |
| ▸ | HTR2B | P41595 | 2/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | HTR1A | P08908 | 1/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.85 |
| ▸ | DRD4 | P21917 | 12/20 | 0.61 |
| ▸ | DRD2 | P14416 | 8/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7369773 | 0.95 | DRD3 (0.77) | DRD3CYP3A4CYP1A2ADRA2ACYP2C9 | |
| SCHEMBL7373070 | 0.93 | DRD3 (0.74) | DRD3CYP3A4CYP1A2ADRA2ACYP2C9 | |
| SCHEMBL7376381 | 0.92 | DRD3 (0.77) | DRD3CYP3A4CYP1A2ADRA2ACYP2C9 | |
| Mosapride SCHEMBL29400580 | 0.92 | DRD3 (1.00) | DRD3CYP3A4CYP1A2ADRA2ACYP2C9 | |
| Mosapride SCHEMBL16417 | 0.92 | DRD3 (1.00) | DRD3CYP3A4CYP1A2ADRA2ACYP2C9 | |
| Mosapride SCHEMBL6228981 | 0.92 | DRD3 (1.00) | DRD3CYP3A4CYP1A2ADRA2ACYP2C9 | |
| SCHEMBL7371801 | 0.92 | DRD3 (0.72) | DRD3CYP3A4CYP1A2ADRA2ACYP2C9 | |
| SCHEMBL1502026 | 0.91 | DRD4 (0.73) | DRD3CYP3A4CYP1A2ADRA2ACYP2C9 | |
| SCHEMBL7365342 | 0.91 | DRD3 (0.76) | DRD3CYP3A4CYP1A2ADRA2ACYP2C9 | |
| Mosapride SCHEMBL6227991 | 0.91 | DRD3 (0.98) | DRD3CYP3A4CYP1A2ADRA2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4870074-A | Substituted benzamide derivatives, for enhancing gastrointestinal motility | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | claimed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| WO-2010021681-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-02-25 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| EP-0243959-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1992-08-19 | — | — | EP | disclosed |
| US-4870074-A | Substituted benzamide derivatives, for enhancing gastrointestinal motility | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0243959-A1 | Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | DRD3 80/4885CYP3A4 403/4885CYP1A2 588/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | DRD3 2912/4885CYP3A4 1342/4885CYP1A2 1154/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | DRD3 3220/4885CYP3A4 1741/4885CYP1A2 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.